Figure 3.

(A) ImmTAC molecules are T cell receptor (TCR) x anti-CD3 bispecific fusion proteins that mimic the immune synapse formed by a natural T-cell–cancer cell interaction. (B,C) Recognition of specific peptide-HLA complexes presented on the cancer cell surface via the affinity-enhanced TCR targeting domain enables recruitment and activation of polyclonal T cells via the CD3-specific effector domain resulting in the targeted release of cytokines and cytolytic mediators to induce cancer cell lysis.